Bispecific antibodies retarget murine T cell cytotoxicity against syngeneic breast cancer in vitro and in vivo
✍ Scribed by M. Belen Moreno; Julie A. Titus; Michael S. Cole; J. Yun Tso; Nhat Le; Chang H. Paik; Tibor Bakács; Charles M. Zacharchuk; David M. Segal; John R. Wunderlich
- Publisher
- Springer-Verlag
- Year
- 1995
- Tongue
- English
- Weight
- 946 KB
- Volume
- 40
- Category
- Article
- ISSN
- 0340-7004
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
A bispecific monoclonal antibody (BsMAb) recognising carcinoembryonic antigen (CEA) and doxorubicin (Dox) was used in colorimetric microcytotoxicity assays with 3 human colon cancer cell lines (COLO320DM, SKCO1 and LS174T) showing no, high or medium CEA expression, respectively. The IC50 values for
## Interleukin -I I (rhlL-I I) is a cytokine that has been shown to enhance the recovery of bone marrow and intestinal crypt cells after cytotoxic insult with radiation or anticancer drugs. The current study examined the effects of rhlL-I I on the response of CEM human lymphoblastic leukemia cells
## Abstract Here we characterize the antitumor activity of a recombinant bispecific single‐chain antibody isolated from the serum of cloned transgenic cows. The antibody, termed r28M, is directed to a melanoma‐associated proteoglycan, also expressed on glioblastoma cells, and to human CD28. Bound t
Ly-6C+ cells constitute 13 +/- 3% of freshly isolated (CBA x C57BL/6)F1 mouse spleen leukocytes. Three distinct populations were identified: CD3 epsilon +NK-1.1- conventional T cells (6%), CD3 epsilon -NK-1.1- granulocytes (5%) and CD3 epsilon +NK-1.1+ T cells (approximately 2%). The CD3 epsilon +NK